Bone Biologics Corporation (BBLG)
NASDAQ: BBLG · Real-Time Price · USD
0.8195
+0.0195 (2.44%)
Apr 1, 2025, 9:40 AM EDT - Market open

Company Description

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein.

The company’s medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration.

It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company’s NELL-1 platform technology used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine.

The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications.

Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Bone Biologics Corporation
Bone Biologics logo
Country United States
Founded 2004
Industry Medical Devices
Sector Healthcare
Employees 2
CEO Jeffrey Frelick

Contact Details

Address:
2 Burlington Woods Drive, Suite 100
Burlington, Massachusetts 01803
United States
Phone 781 552 4452
Website bonebiologics.com

Stock Details

Ticker Symbol BBLG
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001419554
CUSIP Number 098070303
ISIN Number US0980705018
Employer ID 42-1743430
SIC Code 3842

Key Executives

Name Position
Jeffrey Frelick Chief Executive Officer and President
Deina H. Walsh CPA Chief Financial Officer

Latest SEC Filings

Date Type Title
Feb 26, 2025 10-K Annual Report
Dec 13, 2024 8-K Current Report
Dec 13, 2024 424B5 Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 10-Q Quarterly Report
Nov 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 21, 2024 8-K Current Report
Oct 4, 2024 8-K Current Report
Sep 27, 2024 8-K Current Report
Sep 27, 2024 424B5 Filing